GNL Gut and Liver
  1. Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2021;36:1317
    https://doi.org/10.1111/jgh.15355
  2. Edouard Reizine, Julia Chalaye, Sebastien Mule, Helene Regnault, Clara Perrin, Julien Calderaro, Alexis Laurent, Giuliana Amaddeo, Hicham Kobeiter, Vania Tacher, Emmanuel Itti, Alain Luciani. Utility of Early Posttreatment PET/CT Evaluation Using FDG or 18F-FCH to Predict Response to 90Y Radioembolization in Patients With Hepatocellular Carcinoma. American Journal of Roentgenology 2022;218:359
    https://doi.org/10.2214/AJR.21.26485
  3. Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alexander Philipp, Thomas Berg, Heinz J. Klümpen, Julia Benckert, Maciej Pech, Antonio Gasbarrini, Holger Amthauer, Peter Bartenstein, Bruno Sangro, Peter Malfertheiner, Jens Ricke, Max Seidensticker. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging 2022;49:4716
    https://doi.org/10.1007/s00259-022-05920-8
  4. Zhenkang Qiu, Chunpeng Yu, Xiaofei Qiu, Qun Li, Jian Li, Zhao Chen, Shuai Chang, Shuo Zhang, Gang Fan, Song Wang. Safety and Efficacy of CT-Guided Iodine-125 Brachytherapy for Portal Vein Tumor Thrombus in Hepatocellular Carcinoma. Academic Radiology 2023
    https://doi.org/10.1016/j.acra.2023.02.006
  5. Chenyu Liu, George Tadros, Quinn Smith, Linda Martinez, James Jeffries, Zhiyong Yu, Qian Yu. Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis. Front. Oncol. 2022;12
    https://doi.org/10.3389/fonc.2022.887653
  6. Peiyi Xie, Hong Zheng, Haiyang Chen, Kaikai Wei, Ximin Pan, Qinmei Xu, Yongchen Wang, Changguan Tang, Olivier Gevaert, Xiaochun Meng. Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival. BMC Cancer 2021;21
    https://doi.org/10.1186/s12885-021-08944-9
  7. Godefroy Aujay, Frédéric Debordeaux, Jean-Frederic Blanc, Bruno Lapuyade, Panteleimon Papadopoulos, Laurence Bordenave, Hervé Trillaud, Jean-Baptiste Pinaquy. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma. 2021;42:633
    https://doi.org/10.1097/MNM.0000000000001383
  8. Sang Hyun Hwang, Hye-Suk Hong, Dongwoo Kim, Gyoung Min Kim, Hye Won Lee, Misu Lee, Do Young Kim, Mi-Ae Park, Mijin Yun. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. Clin Nucl Med 2022;47:e437
    https://doi.org/10.1097/RLU.0000000000004128
  9. Jung Woo Eun, Jung Hwan Yoon, Hye Ri Ahn, Seokhwi Kim, Young Bae Kim, Su Bin Lim, Won Park, Tae Wook Kang, Geum Ok Baek, Moon Gyeong Yoon, Ju A Son, Ji Hyang Weon, Soon Sun Kim, Hyo Jung Cho, Jae Youn Cheong. Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Communications 2023
    https://doi.org/10.1002/cac2.12414
  10. Zersenay Alem, Timothy E. Murray, Csilla Egri, John Chung, David Liu, Khaled M. Elsayes, Silvia D. Chang, Alison Harris. Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma. Abdom Radiol 2021;46:3596
    https://doi.org/10.1007/s00261-021-03095-8
  11. Bohyun Kim, Soon Sun Kim, Sung Won Cho, Jae Youn Cheong, Jimi Huh, Jai Keun Kim, Jei Hee Lee, Hye Ri Ahn, Hyo Jung Cho. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507
    https://doi.org/10.1007/s00330-020-07357-9
  12. Yanmei Dai, Huijie Jiang, Shi-Ting Feng, Yuwei Xia, Jinping Li, Sheng Zhao, Dandan Wang, Xu Zeng, Yusi Chen, Yanjie Xin, Dongmin Liu. Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma. JHC 2022;Volume 9:273
    https://doi.org/10.2147/JHC.S351077
  13. Bo Hyun Kim. Selecting the Right Tool for the Right Job: Which Response Criteria Better Predicts Survival of Patients Treated with Transarterial Radioembolization?. Gut and Liver 2020;14:671
    https://doi.org/10.5009/gnl20324
  14. Naik Vietti Violi, Jeffrey Gnerre, Amy Law, Stefanie Hectors, Octavia Bane, John Doucette, Ghadi Abboud, Edward Kim, Myron Schwartz, M Isabel Fiel, Bachir Taouli. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. Eur Radiol 2022;32:6493
    https://doi.org/10.1007/s00330-022-08732-4
© 2023. Gut and Liver. / Powered by INFOrang Co., Ltd